Abstract:Brain aging is characterized by a decrease in N‐methyl D‐aspartate mediated glutamate‐stimulated release of norepinephrine in the cerebral cortex. Proposed target sites for pharmacological restoration of deficits in norepinephrine release in the aging brain include blockade of alpha‐2 adrenergic receptors using mirtazapine or idazoxan, and targeting the norepinephrine reuptake inhibitor with the CNS stimulant methylphenidate. Aging affects virtually all organs of the body, but perhaps it has the most profound effects on the brain and its neurotransmitter systems, which influence a wide range of crucial functions, such as attention, focus, mood, neuroendocrine and autonomic functions, and sleep cycles. All of these essential functions, as well as fundamental cognitive processes such as memory, recall, and processing speed, utilize neuronal circuits that depend on neurotransmitter signaling between neurons. Glutamate (Glu), the main excitatory neurotransmitter in the CNS, is involved in most neuronal excitatory functions, including release of the neurotransmitter norepinephrine (NE). Previous studies from our lab demonstrated that the age‐associated decline in Glu‐stimulated NE release in rat cerebral cortex and hippocampus mediated by NMDA glutamate receptors, as well as deficits in dendritic spines, and cognitive functions are fully rescued by the CNS stimulant amphetamine. Here we further investigated Glu‐stimulated NE release in the cerebral cortex to identify additional novel target sites for restoration of Glu‐stimulated NE release. We found that blockade of alpha‐2 adrenergic receptors fully restores Glu‐stimulated NE release to the levels of young controls. In addition, we investigated the density and responsiveness of NMDA receptors as a potential underlying neuronal mechanism that could account for the observed age‐associated decline in Glu‐stimulated NE release. In the basal state of the receptor (no added glutamate and glycine) the density of NMDA receptors in the cortex from young and aged rats was similar. However, in contrast, in the presence of 10 μM added glutamate, which opens the receptor channel and increases the number of available [3H]‐MK‐801 binding sites within the channel, the density of [3H]‐MK‐801 binding sites was significantly less in the cortex from aged rats.

Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells

Microglia Impede Oligodendrocyte Generation in Aged Brain

Restoring Nuclear Entry of Sirtuin 2 in Oligodendrocyte Progenitor Cells Promotes Remyelination During Ageing

Clemastine Ameliorates Myelin Deficits via Preventing Senescence of Oligodendrocytes Precursor Cells in Alzheimer’s Disease Model Mouse

169. Combining Metformin and Clemastine for Enhanced Remyelination in Multiple Sclerosis

Clemastine Induces Oligodendrocyte Progenitor Pool Exhaustion and Senescence in the Context of Chronic Demyelination in a Rabbit Model

Clemastine Induces an Impairment in Developmental Myelination

The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation

Pro-myelinating clemastine administration improves recording performance of chronically implanted microelectrodes and nearby neuronal health

Metformin promotes CNS remyelination and improves social interaction following focal demyelination through CBP Ser436 phosphorylation

Senescent-like microglia limit remyelination through the senescence associated secretory phenotype

HB-EGF and EGF infusion following CNS demyelination mitigates age-related decline in regeneration of oligodendrocytes from neural precursor cells originating in the ventricular-subventricular zone

Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury

Impaired metabolism of oligodendrocyte progenitor cells and axons in demyelinated lesion and in the aged CNS

Clemastine Enhances Myelination, Delays Axonal Loss and Promotes Functional Recovery in Spinal Cord Injury

Age-related decline in oligodendrogenesis retards white matter repair in mice

Navigating oligodendrocyte precursor cell aging in brain health

Pharmacological target sites for restoration of age‐associated deficits in NMDA receptor‐mediated norepinephrine release in brain

Regulation of Oligodendrocyte Functions: Targeting Lipid Metabolism and Extracellular Matrix for Myelin Repair

Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease

M2 Microglia and Macrophages Drive Oligodendrocyte Differentiation During CNS Remyelination